Though a rare condition, the debilitating wasting disease spinal muscular atrophy is gaining a large biopharma interest (and price tags in the millions of dollars), and Roche, with partner PTC Therapeutics, are the latest companies to show their hand in improving kids’ ability to move with the genetic disorder.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,